Elkind Mitchell S V, Leon Vladimir, Moon Yeseon P, Paik Myunghee C, Sacco Ralph L
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Stroke. 2009 Oct;40(10):3233-7. doi: 10.1161/STROKEAHA.109.552802. Epub 2009 Jul 30.
High-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are hypothesized to be biomarkers of systemic inflammation and risk of myocardial infarction (MI) and stroke. Little is known, however, about the stability of these markers over time, and in particular, about the effects of acute vascular events on these marker levels.
Serum samples were collected at 4 annual intervals in 52 stroke-free participants from the Northern Manhattan Study (NOMAS) and assayed for hsCRP and Lp-PLA2 mass and activity levels using standard techniques. Log transformation of levels was performed as needed to stabilize the variance. Stability of marker levels over time was assessed using random effects models unadjusted and adjusted for demographics and other risk factors. In addition, samples from 37 initially stroke-free participants with stroke (n=17) or MI (n=20) were available for measurement before and after the vascular event (median 5 days, range 2 to 40 days). Levels before and after events were compared using nonparametric tests.
HsCRP and Lp-PLA2 activity levels were stable over time, whereas Lp-PLA2 mass levels decreased on average 5% per year (P=0.0015). Using accepted thresholds to define risk categories of Lp-PLA2 mass, there was no significant change over time. HsCRP increased after stroke (from median 2.2 mg/L prestroke to 6.5 mg/L poststroke; P=0.0067) and MI (from median 2.5 mg/L pre-MI to 13.5 mg/L post-MI; P<0.0001). Lp-PLA2 mass and activity levels both decreased significantly after stroke and MI (for Lp-PLA2 mass, from median 210.0 ng/mL to 169.4 ng/mL poststroke, P=0.0348, and from median 233.0 ng/mL to 153.9 post-MI, P<0.0001).
Lp-PLA2 mass levels decrease modestly, whereas hsCRP and Lp-PLA2 activity appear stable over time. Acutely after stroke and MI, hsCRP increases whereas Lp-PLA2 mass and activity levels decrease. These changes imply that measurements made soon after stroke and MI are not reflective of prestroke levels and may be less reliable for long-term risk stratification.
高敏C反应蛋白(hsCRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)被认为是全身炎症以及心肌梗死(MI)和中风风险的生物标志物。然而,对于这些标志物随时间的稳定性,尤其是急性血管事件对这些标志物水平的影响,我们知之甚少。
从北曼哈顿研究(NOMAS)中选取52名无中风参与者,每隔一年采集一次血清样本,采用标准技术检测hsCRP、Lp-PLA2的质量和活性水平。根据需要对水平进行对数转换以稳定方差。使用未调整以及针对人口统计学和其他风险因素进行调整的随机效应模型评估标志物水平随时间的稳定性。此外,37名最初无中风的参与者发生中风(n = 17)或心肌梗死(n = 20),可获取血管事件发生前后(中位数5天,范围2至40天)的样本进行测量。使用非参数检验比较事件前后的水平。
hsCRP和Lp-PLA2活性水平随时间稳定,而Lp-PLA2质量水平平均每年下降5%(P = 0.0015)。使用公认的阈值定义Lp-PLA2质量的风险类别,随时间没有显著变化。中风后hsCRP升高(从中风前的中位数2.2 mg/L升至中风后的6.5 mg/L;P = 0.0067),心肌梗死后也升高(从心肌梗死前的中位数2.5 mg/L升至心肌梗死后的13.5 mg/L;P < 0.0001)。中风和心肌梗死后Lp-PLA2质量和活性水平均显著下降(对于Lp-PLA2质量,从中风前的中位数210.0 ng/mL降至中风后的169.4 ng/mL,P = 0.0348,从心肌梗死前的中位数233.0 ng/mL降至心肌梗死后的153.9 ng/mL,P < 0.0001)。
Lp-PLA2质量水平适度下降,而hsCRP和Lp-PLA2活性随时间似乎稳定。中风和心肌梗死后急性期,hsCRP升高,而Lp-PLA2质量和活性水平下降。这些变化表明,中风和心肌梗死后不久进行的测量不能反映中风前的水平,可能对长期风险分层的可靠性较低。